I don't think there is a requirement for further study at this point. It's my own experience, from where I sit at the National Microbiology Laboratory, that there is manufacturing capacity for trial lots, including some in Canada, and that further study is not required. I think we need to move on and figure out how to use this $88 million to advance HIV vaccine research and development, with the recognition that there isn't a need for another bricks and mortar manufacturing facility.
On April 22nd, 2010. See this statement in context.